Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
5.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

4.3K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.3K
Positive Regulator Molecules02:39

Positive Regulator Molecules

7.1K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular Mobility of N-Acetylgalactosamine-Modified Cyclodextrins on a Polyrotaxane for Highly Efficient Liver Targeting of Antibody Chimeras and Genome-Editing Ribonucleoproteins.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A Twin-Fluid Atomization Method for Fabricating Ovalbumin-Loaded Gelatin Microcapsules.

Chemical & pharmaceutical bulletin·2026
Same author

Evaluation of Complex Formation between Aminated Polyrotaxane and Proteins Using FRET.

Chemical & pharmaceutical bulletin·2026
Same author

Molecular and histological characterizations reveal two distinct senescent microglia populations in Niemann-Pick disease type C mouse model.

GeroScience·2026
Same author

Evidence of the Utility of Needle-Free Injectable Devices for Subcutaneous Administration of Biopharmaceuticals: Comparable Study of in vivo Pharmacological and Vaccination Ability to Normal Injection.

Medical devices (Auckland, N.Z.)·2026
Same author

Ultrasound-guided guidewire maneuver to resolve peritoneal drainage catheter obstruction in an infant: A case report.

Radiology case reports·2026

Related Experiment Video

Updated: Mar 30, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.6K

2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent.

Masako Yokoo1, Yasushi Kubota1,2, Keiichi Motoyama3

  • 1Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.

Plos One
|November 5, 2015
PubMed
Summary

2-Hydroxypropyl-β-cyclodextrin (HP-β-CyD) demonstrates anticancer effects by inhibiting leukemic cell proliferation and reducing cholesterol. This cholesterol modifier shows promise as a therapeutic agent for various leukemia types, including resistant mutations, with no significant adverse effects observed in mice.

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.7K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Related Experiment Videos

Last Updated: Mar 30, 2026

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.6K
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

15.7K
Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

11.6K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • 2-Hydroxypropyl-β-cyclodextrin (HP-β-CyD) is an approved pharmaceutical excipient and cholesterol modifier.
  • Cholesterol dysregulation is implicated in various cancers, including leukemia.
  • HP-β-CyD's role as a potential anticancer agent warrants investigation.

Purpose of the Study:

  • To investigate the anticancer effects of HP-β-CyD in leukemia.
  • To determine the mechanism of action and efficacy of HP-β-CyD against diverse leukemic cell lines and patient samples.

Main Methods:

  • In vitro testing of HP-β-CyD against acute myeloid leukemia (AML), acute lymphoblastic leukemia, and chronic myeloid leukemia (CML) cell lines.
  • Assessment of intracellular cholesterol levels, cell-cycle progression (G2/M arrest), and apoptosis following HP-β-CyD treatment.
  • In vivo studies using leukemia mouse models and evaluation of colony-forming ability in primary human leukemia cells.

Main Results:

  • HP-β-CyD significantly inhibited leukemic cell proliferation by reducing intracellular cholesterol, inducing G2/M cell-cycle arrest, and promoting apoptosis.
  • HP-β-CyD improved survival in leukemia mouse models and inhibited colony formation in primary AML and CML cells.
  • Anticancer effects were observed against T315I BCR-ABL mutated CML cells and hypoxia-adapted CML cells with stem-like properties. Systemic administration showed no significant adverse effects.

Conclusions:

  • HP-β-CyD exhibits potent anticancer activity against various leukemia types, irrespective of specific disease or cellular characteristics.
  • HP-β-CyD's ability to modify cholesterol metabolism presents a novel therapeutic strategy for leukemia.
  • HP-β-CyD is a promising anticancer agent with a favorable safety profile for clinical development.